Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.